Masimo Announces Preliminary Q4 FY23 Revenue Of $541M-$551M Versus Consensus Of $538.38M, Including Healthcare Revenue Of $336M-$341M And Non-Healthcare Revenue Of $205M-$210M
Portfolio Pulse from Benzinga Newsdesk
Masimo Corporation has announced preliminary Q4 FY23 revenue figures ranging between $541M-$551M, surpassing the consensus estimate of $538.38M. The revenue is split between healthcare, which is expected to be between $336M-$341M, and non-healthcare, projected to be $205M-$210M.
January 10, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Masimo Corporation's preliminary Q4 FY23 revenue beat consensus estimates, indicating a potential positive impact on its stock price in the short term.
Beating revenue estimates typically leads to positive investor sentiment and can cause a short-term increase in stock price. Masimo's announcement of higher-than-expected revenue for both healthcare and non-healthcare segments suggests strong performance, which is likely to be viewed favorably by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100